Rapid Micro Biosystems (NASDAQ:RPID) CFO Sells $22,782.06 in Stock

Rapid Micro Biosystems, Inc. (NASDAQ:RPID) CFO Sean Wirtjes sold 6,027 shares of the stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $3.78, for a total value of $22,782.06. Following the transaction, the chief financial officer owned 483,928 shares in the company, valued at $1,829,247.84. This trade represents a 1.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Rapid Micro Biosystems Price Performance

NASDAQ:RPID traded up $0.33 during mid-day trading on Tuesday, reaching $4.08. The stock had a trading volume of 306,371 shares, compared to its average volume of 371,737. The stock has a market capitalization of $180.83 million, a P/E ratio of -4.04 and a beta of 1.38. The firm has a 50 day moving average price of $3.66 and a two-hundred day moving average price of $3.39. The company has a debt-to-equity ratio of 0.42, a quick ratio of 2.95 and a current ratio of 4.23. Rapid Micro Biosystems, Inc. has a one year low of $1.86 and a one year high of $4.94.

Rapid Micro Biosystems (NASDAQ:RPID) last announced its quarterly earnings data on Friday, November 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.26). Rapid Micro Biosystems had a negative net margin of 145.11% and a negative return on equity of 73.90%. The company had revenue of $7.84 million during the quarter, compared to analysts’ expectations of $7.60 million. As a group, analysts expect that Rapid Micro Biosystems, Inc. will post -1.1 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Wall Street Zen lowered shares of Rapid Micro Biosystems from a “hold” rating to a “sell” rating in a report on Saturday, January 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rapid Micro Biosystems in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $8.00.

Institutional Investors Weigh In On Rapid Micro Biosystems

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in Rapid Micro Biosystems by 6.7% during the third quarter. Vanguard Group Inc. now owns 965,018 shares of the company’s stock valued at $3,223,000 after purchasing an additional 60,655 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Rapid Micro Biosystems by 6.3% in the fourth quarter. Geode Capital Management LLC now owns 217,568 shares of the company’s stock worth $631,000 after buying an additional 12,881 shares during the period. Evernest Financial Advisors LLC raised its stake in shares of Rapid Micro Biosystems by 355.1% in the third quarter. Evernest Financial Advisors LLC now owns 200,234 shares of the company’s stock worth $669,000 after buying an additional 156,234 shares during the period. Susquehanna International Group LLP lifted its position in shares of Rapid Micro Biosystems by 12.6% during the 3rd quarter. Susquehanna International Group LLP now owns 58,387 shares of the company’s stock valued at $195,000 after buying an additional 6,528 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of Rapid Micro Biosystems by 37.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 55,642 shares of the company’s stock valued at $186,000 after acquiring an additional 15,255 shares during the period. 52.60% of the stock is currently owned by hedge funds and other institutional investors.

Rapid Micro Biosystems Company Profile

Rapid Micro Biosystems (NASDAQ: RPID) develops and commercializes automated microbial detection and contamination control solutions for the life sciences industry. Its flagship offering, the Growth Direct® System, leverages digital imaging and proprietary growth indicator plates to identify and count microorganisms more rapidly than traditional culture-based methods. The company’s technology platform is designed to streamline quality control workflows in pharmaceutical, biotechnology and vaccine manufacturing settings, helping clients reduce release times and improve operational efficiency.

In addition to the Growth Direct® System, Rapid Micro Biosystems offers an integrated suite of software and consumables that support automated data capture, analysis and reporting.